cagrilintide semaglutide Efficacy and safety of co-administered once-weekly 2·4 mg with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Subcutaneous Cagrilintide, Semaglutide Shows Significant

This is consistent, the team said, with the prevailing hypothesis suggesting that [semaglutides] therapeutic effects arise from overlapping neurobiological mechanisms that modulate both metabolic regulation and reward-related pathways shared between obesity and alcohol use disorder. The team concluded: Findings from this trial provide support for broadening the indication for semaglutide to [include] AUD in patients with a BMI of 30 or greater, which could benefit millions. About 890 million adults globally have a BMI over 30, and in the U.S., 8 million adults are estimated to have obesity and high alcohol consumption

Weight loss indications often face insurance coverage challenges

Mechanisms by which IGF-I may promote cancer

For the detailed liver pathways involved, review liver detoxification, glutathione and bile

Ania Jastreboff, an obesity medicine physician scientist at Yale University School of Medicine/Yale School of Medicine, co-Director of the Yale Center for Weight Management and the lead author on the phase 2 study, said that the results were striking and concluded that Retatrutide holds promise for substantial weight reduction in adults with obesity over a 48-week period